Sanofi announces entering the RSV vacc. market for children
By Whang, byung-woo | translator Hong, Ji Yeon
24.12.04 05:00:18
가나다라
0
To be marketed in South Korea in early 2025, targeting newborns·infants during their first RSV season
Ki Wook Yun, Professor of Seoul National University, "There are unmet needs for RSV prevention, the introduction of Beyfortus is meaningful"
Sanofi focuses on improving RSV disease awareness…long term goal is to enter the NIP
Sanofi has announced the launch of Beyfortus, an injectable antibody drug to prevent respiratory syncytial virus (RSV) lower respiratory tract disease, for the first time in South Korea. The company aims to take a market share.
As clinical practices are in high demand for the vaccine, proactive RSV prevention will become possible following the launch of Beyfortus.
▲Sanofi held a press conference to showcase the preventative effects of its Beyfortus (active ingredient: nirsevimab), an injectable antibody drug for infants to prevent RSV lower respiratory tract disease (left: Ki Wook Yun, Professor of Seoul National University College of Medicine).
On December 3, Sanofi held a press conference introducing the preventative effects of its Beyfortus (active ingredient: nirsevimab), an injectable antibody drug to prevent RSV lower respiratory tract disease for infants.
Beyfortus was approved by the Ministry of Food and Drug Safety (MFDS) in May as an inj
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)